Mervyn Forman is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
975 Johnson Ferry Rd NE
Ste 340
Atlanta, GA 303421619
Telephone
404-256-0121Registry record last updated 17 Jan 2008.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20252 payments
- Amgen Inc.Program year20251 payment
- Novo Nordisk IncProgram year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.3%Statin19.5%Rosuvastatin Calcium42%Atorvastatin Calcium33%Pravastatin Sodium26%Part D≥56 patientsBeta blocker12.4%Metoprolol Succinate31%Metoprolol Tartrate22%Sotalol18%Carvedilol18%Nebivolol Hcl11%Part D<11 patients+ 9 more classes in this area
Metabolism & gastrointestinal
13.6%Biguanide (metformin)3.9%Metformin Hcl85%Metformin Hcl Er15%Part D<11 patientsGLP-1 receptor agonist2.8%Ozempic100%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
8.9%l-Thyroxine8.9%Levothyroxine Sodium88%Synthroid12%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2024 per NIH RePORTER. The latest:
- Development of Novel Adenosine Polymers for Coating Medical Devices
Adenopaint, Llc
FY2018$567,471R44HL136233
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”